If new technical solutions are to be used as an integrated part of publicly financed health care, it needs to be supported by solid, clinical data published in peer-reviewed scientific journals, it needs to free health care resources and put the tax-payers money to good use. Given these arguably objective truths, it was an obvious choice for us to support clinical trials to study the potential efficacy of OPTILOGG®.
Today four independent clinical trials have studied the effects of OPTILOGG®, recruiting 362 elderly people suffering from heart failure. An analysis of these studies shows that OPTILOGG® reduces the need for in-hospital care by 38%, and increases event-free survival by 50%, while also improving health-related quality of life. These outcomes are the effects of a significantly improved self-care behaviour, which means that the clinical impact is achieved without having to spend health care resources on monitoring or acting on data. OPTILOGG® is developed for the specific population and shows a mean system adherence of 92% after six months, which is the highest published system adherence in the world. OPTILOGG® is the only solution on the market with hard clinical data to prove that we reduce the health care burden in a cost-efficient manner.
A complete meta-analysis is provided below.
RCT – Randomized controlled trial, n – antal, NYHA – New York Heart Association, HFpEF – HF with preserved ejections-fraction, AF – atrial fibrillation, COPD – chronic obstructive pulmonary disease, HTN – hypertension, ACEi – angiotensin converting enzyme inhibitor, ARB – angiotensin receptor blocker, MRA – mineralocorticoid receptor antagonist
Copyright © All rights reserved